Ahmed, ShazaTaha Mohamed, HossamEl-Husseiny, NouraEl Mahdy, Manal MSafwat, GehanDiab, Ayman AEl-Sherif, Ahmed AEl-Shinawi, MohamedMohamed, Mona Mostafa2021-03-052021-03-0503/02/2021https://doi.org/10.1016/j.bbamcr.2021.118995https://qrgo.page.link/eYhs8Locally advanced breast cancer (LABC) is an aggressive disease characterized by late clinical presentation, large tumor size, treatment resistance and low survival rate. Expression of EGFR/HER2 and activation of intracellular tyrosine kinase domains in LABC are associated with poor prognosis. Thus, target therapies such as the anti-receptor tyrosine kinases lapatinib drug have been more developed in the past decade. The response to lapatinib involves the inhibition of RTKs and subsequently signaling molecules such as Src/STAT3/Erk1/2 known also to be activated by the cytokines in the tumor microenvironment (TME). The aim of the present study is to identify the major cytokine that might contribute to lapatinib resistance in EGFR+/HER2+ LABC patients. Indeed, tumor associated macrophages (TAMs) are the main source of cytokines in the TME. Herein, we isolated TAMs from LABC during modified radical mastectomy (MRM). Cytokine profile of TAMs revealed that IL-8 is the most prominent highly secreted cytokine by TAMs of LABC patients. Using in-vitro cell culture model we showed that recombinant IL-8 (50 and 100 ng/mL) at different time intervals interfere with lapatinib action via activation of Src/EGFR and signaling molecules known to be inhibited during treatment. We proposed that to improve LABC patients' response to lapatinib treatment it is preferred to use combined therapy that neutralize or block the action of IL-8.en-USSrc, STAT3 and Erk1/2.SrcLocally advanced breast cancerEGFRHER2tumor associated macrophagesArticlehttps://doi.org/10.1016/j.bbamcr.2021.118995